KRAS and lung adenocarcinoma: Panobiostat sensitized lung adenocarcinoma cells including cells with K-ras (Kirsten rat sarcoma viral oncogene homolog) or epidermal growth factor receptor (EGFR) mutation to the anti-proliferative effects of the tyrosine kinase inhibitor erlotinib in the in vitro experiment [148].